Japanese Hospitality Stock News

TSE:6723
TSE:6723Semiconductor

Renesas Electronics (TSE:6723) Quarterly Profit Challenges Trailing Twelve Month Loss Narrative

Renesas Electronics (TSE:6723) has wrapped up FY 2025 with fourth quarter revenue of ¥351,537 million and basic EPS of ¥9.55, compared with a trailing 12 month EPS loss of ¥28.55 on revenue of ¥1.32 trillion. Over the past few quarters, the company’s revenue has moved from ¥292,600 million in Q4 FY 2024 to ¥351,537 million in Q4 FY 2025, while quarterly EPS has ranged from a loss of ¥33.38 in Q2 FY 2025 to ¥58.66 in Q3 FY 2025. This points to a situation where top line scale is holding, but...
TSE:8058
TSE:8058Trade Distributors

Mitsubishi (TSE:8058) Margin Compression Challenges Bullish Narratives Despite Solid Q3 EPS

Mitsubishi (TSE:8058) has posted its Q3 2026 numbers with revenue of ¥5.0 trillion and basic EPS of ¥67.36, backed by net income of ¥252.13 billion. This keeps the focus firmly on how efficiently it is converting a large top line into profits. The company has seen revenue move from ¥4.6 trillion in Q3 2025 to ¥5.0 trillion in Q3 2026, while basic EPS shifted from ¥52.65 to ¥67.36 over the same period, giving investors more detail to weigh that earnings profile against softer net profit...
TSE:7733
TSE:7733Medical Equipment

How Olympus’ EAGLE Trial AI Endoscopy Results Could Impact Olympus (TSE:7733) Investors

Olympus Corporation recently announced positive multicenter EAGLE Trial results for its FDA-cleared and CE-marked CADDIE AI device, showing improved real-time polyp and adenoma detection during colonoscopy without disrupting safety or workflow. The trial underscores Olympus’s push to embed cloud-based AI into its OLYSENSE Intelligent Endoscopy Ecosystem, potentially strengthening the clinical appeal of its endoscopy platform for hospitals and gastroenterologists. We’ll now examine how the...